← Browse by Condition
Medical Condition

hepatocellular carcinoma

Total Trials
43
Recruiting Now
43
Trial Phases
Phase 1, Phase 3, Phase 2, Phase 3

ClinicalMetric tracks all active clinical trials for hepatocellular carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — hepatocellular carcinoma Clinical Trials

How many clinical trials are currently recruiting for hepatocellular carcinoma?
ClinicalMetric currently tracks 43 actively recruiting clinical trials for hepatocellular carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 43. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for hepatocellular carcinoma?
hepatocellular carcinoma research spans Phase 1 (8 trials), Phase 2 (14 trials), Phase 3 (4 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a hepatocellular carcinoma clinical trial?
Eligibility criteria for hepatocellular carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
8
Phase 2
14
Phase 3
4
Top Sponsors
Sun Yat-sen University 2 trials
National Taiwan University Hospital 2 trials
Second Affiliated Hospital of Guangzhou Medical University 2 trials
University of Aarhus 2 trials
National University Hospital, Singapore 1 trial

Recruiting Clinical Trials

NCT05687747 Phase 1
Recruiting
Single Centre Prospective Evaluation of 68Gallium-FAPI PET/MRI in Hepatocellular Carcinoma
Enrollment
100 pts
Location
Singapore
Sponsor
National University Hospital, ...
View Trial →
NCT06950827
Recruiting
Textbook Outcomes of Right Hemihepatectomy in Patients With Hepatocellular Carcinoma
Enrollment
400 pts
Location
China
Sponsor
West China Hospital
View Trial →
NCT06201065 Phase 3
Recruiting
FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
Enrollment
200 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →
NCT06363006 Phase 1
Recruiting
Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer
Enrollment
40 pts
Location
China
Sponsor
Peking Union Medical College H...
View Trial →
NCT07395635
Recruiting
Phase II Trial of Immunonutrition in Hepatectomy
Enrollment
100 pts
Location
India
Sponsor
Tata Memorial Centre
View Trial →
NCT07485114
Recruiting
Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors
Enrollment
300 pts
Location
Israel
Sponsor
Daniel Keizman
View Trial →
NCT06109272 Phase 2, Phase 3
Recruiting
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
Enrollment
660 pts
Location
United States, Franc...
Sponsor
AbbVie
View Trial →
NCT04595864 Phase 3
Recruiting
Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation
Enrollment
40 pts
Location
China
Sponsor
The Affiliated Nanjing Drum To...
View Trial →
NCT05201404 Phase 3
Recruiting
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
Enrollment
471 pts
Location
United States, Bosni...
Sponsor
Can-Fite BioPharma
View Trial →
NCT06880523 Phase 2
Recruiting
STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma
Enrollment
140 pts
Location
Canada
Sponsor
Canadian Cancer Trials Group
View Trial →
NCT04348838
Recruiting
Prospective Cohort of Patients With Hepatocellular Carcinoma in France
Enrollment
5,000 pts
Location
France
Sponsor
Centre Hospitalier Universitai...
View Trial →
NCT06632717 Phase 2
Recruiting
Hepatic Arterial Infusion Chemotherapy With Lipiodol Embolization in Advanced Hepatocellular Carcinoma
Enrollment
24 pts
Location
Taiwan
Sponsor
National Taiwan University Hos...
View Trial →
NCT04803318 Phase 2
Recruiting
Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
Enrollment
100 pts
Location
China
Sponsor
Second Affiliated Hospital of ...
View Trial →
NCT06345508
Recruiting
Early Detection of Liver Cancer by QUS
Enrollment
328 pts
Location
Canada
Sponsor
Centre hospitalier de l'Univer...
View Trial →
NCT07246668 Phase 2
Recruiting
A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma
Enrollment
52 pts
Location
South Korea
Sponsor
Yonsei University
View Trial →
NCT07179900 Phase 2
Recruiting
Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
Enrollment
60 pts
Location
China
Sponsor
Hebei Medical University Fourt...
View Trial →
NCT05502198
Recruiting
Relevance of Sarcopenia in Advanced Liver Disease
Enrollment
150 pts
Location
Sweden
Sponsor
Linkoeping University
View Trial →
NCT04340986
Recruiting
Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma
Enrollment
1,250 pts
Location
France
Sponsor
Assistance Publique - Hôpitaux...
View Trial →
NCT06242470 Phase 1
Recruiting
A Study of MGC026 in Participants With Advanced Solid Tumors
Enrollment
250 pts
Location
United States, Austr...
Sponsor
MacroGenics
View Trial →
NCT05994859
Recruiting
SIRT for Potentially Resectable HCC
Enrollment
35 pts
Location
China
Sponsor
Second Affiliated Hospital of ...
View Trial →
NCT05359939
Recruiting
A Head-to-head Comparison of MRI, CT, 18F-FDGal and 18F-choline in Patients With Hepatocellular Carcinoma
Enrollment
50 pts
Location
Denmark
Sponsor
University of Aarhus
View Trial →
NCT04510129
Recruiting
A Multicenter Cancer Biospecimen Collection Study
Enrollment
1,650 pts
Location
United States
Sponsor
Cofactor Genomics, Inc.
View Trial →
NCT05926726
Recruiting
GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma
Enrollment
12 pts
Location
China
Sponsor
RenJi Hospital
View Trial →
NCT06542796
Recruiting
Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma
Enrollment
100 pts
Location
China
Sponsor
Second Affiliated Hospital, Zh...
View Trial →
NCT06905262
Recruiting
Tumor Antigen Discovery for Innovative Cancer Immunotherapies in HCC: from Benchside to Bedside (HepAnt)
Enrollment
70 pts
Location
Italy
Sponsor
National Cancer Institute, Nap...
View Trial →
NCT04864054 Phase 1, Phase 2
Recruiting
GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
Enrollment
60 pts
Location
United States, Taiwa...
Sponsor
Eureka Therapeutics Inc.
View Trial →
NCT05971108
Recruiting
Real-world Elecsys® GAAD Implementation and Validation to Improve Surveillance and Early Detection of HCC
Enrollment
600 pts
Location
United Kingdom
Sponsor
Manchester University NHS Foun...
View Trial →
NCT06558227 Phase 2
Recruiting
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
Enrollment
90 pts
Location
China
Sponsor
Suzhou Zelgen Biopharmaceutica...
View Trial →
NCT05520788
Recruiting
Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing
Enrollment
200 pts
Location
China
Sponsor
Tongji Hospital
View Trial →
NCT05203120
Recruiting
A National Phase II Study of Proton Therapy in Hepatocellular Carcinoma
Enrollment
50 pts
Location
Denmark
Sponsor
University of Aarhus
View Trial →
NCT06349317 Phase 2
Recruiting
Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
Enrollment
33 pts
Location
China
Sponsor
Yongyi Zeng
View Trial →
NCT07091942
Recruiting
Curative Therapy After Atezolizumab and Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma
Enrollment
1,600 pts
Location
Taiwan
Sponsor
National Taiwan University Hos...
View Trial →
NCT06044506 Phase 1
Recruiting
Autologous Natural Killer Cell Therapy for Hepatocellular Carcinoma
Enrollment
3 pts
Location
Indonesia
Sponsor
Dr Cipto Mangunkusumo General ...
View Trial →
NCT03899428 Phase 2
Recruiting
Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
Enrollment
30 pts
Location
Hong Kong
Sponsor
Humanity & Health Medical Grou...
View Trial →
NCT07145801 Phase 2
Recruiting
Y-90 Treatment Response Using Transarterial Radioembolization
Enrollment
30 pts
Location
United States
Sponsor
Thomas Jefferson University
View Trial →
NCT07227012 Phase 1, Phase 2
Recruiting
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Enrollment
138 pts
Location
United States, Japan...
Sponsor
Pfizer
View Trial →
NCT06789757 Phase 2
Recruiting
The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)
Enrollment
19 pts
Location
United States
Sponsor
Inova Health Care Services
View Trial →
NCT06910657 Phase 1
Recruiting
IDOV-Immune for Advanced Solid Tumors
Enrollment
78 pts
Location
United States, Austr...
Sponsor
ViroMissile, Inc.
View Trial →
NCT06898398
Recruiting
TACE Combined Surgery for the Resectable Huge HCC
Enrollment
326 pts
Location
China
Sponsor
Sun Yat-sen University
View Trial →
NCT06190665
Recruiting
DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC
Enrollment
188 pts
Location
China
Sponsor
Zhongda Hospital
View Trial →
NCT07607769
Recruiting
MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.
Enrollment
200 pts
Location
Italy
Sponsor
AstraZeneca
View Trial →
NCT05276037
Recruiting
Value of Negative 18FDG PET/CT in Milan Out, Up-to-seven in, HCC Transplant Candidates
Enrollment
350 pts
Location
Belgium
Sponsor
University of Liege
View Trial →
NCT06590246 Phase 1, Phase 2
Recruiting
A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)
Enrollment
121 pts
Location
China
Sponsor
Shanghai AbelZeta Ltd.
View Trial →

Related Conditions

liver cancer (3) colorectal cancer (3) non small cell lung cancer (2) liver neoplasms (2) liver cirrhosis (2) small cell lung cancer (2) bladder cancer (2) sarcoma (2) melanoma (2) cervical cancer (2) gastric cancer (2) breast cancer (2)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology